Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 ...

Novo Nordisk said the job cuts will eliminate about 11% of its workforce, with 5,000 of the reductions in Denmark.

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, will cut 9,000 jobs or 11.5% of its workforce in a ...

The maker of the popular weight-loss drug Wegovy announced on Wednesday that it will be cutting 9,000 jobs in the company.

Novo Nordisk, the Danish pharmaceutical giant behind weight-loss drug Wegovy and diabetes treatment Ozempic, announced plans to cut 9,000 jobs, or 11.5% of its global workforce, as part of a major ...

Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals, a healthy balance sheet, and solid management. Recent stock weakness stems from sector-wide regulatory ...

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application ...

Novo Nordisk A/S's FDA approval for Wegovy in MASH and aggressive Ozempic pricing boost its position, despite recent stock declines and competitive pressure from Eli Lilly and Company. Both NVO and ...